About Us:

Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon™ technologies to create new and potentially best-in-class therapies.

Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus. The company continues to expand into additional therapeutic areas to address unmet patient needs.

Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany; Palo Alto and Redwood City, California, and Princeton, New Jersey, United States.


Ascendis Pharma, Inc.
500 Emerson Street
Palo Alto, CA 94301



Considerations for Optimal Long-Acting Growth Hormone (LAGH) Design- Presented by Kennett Sprogøe, PhD

Can a Weekly LAGH Achieve the Same Safety and Efficacy as a Daily hGH?- Presented by Aristides Maniatis, MD

Video Link

Have questions? Please contact:

Enter the MAP Spotlight Raffle